吡柔比星联合西施泰在腺性膀胱炎电切术后膀胱灌注治疗中的应用研究

Investigation of combined medication of Pirarubicin and Haluronicacid （HA） in bladder irrigation on patients with glandular cystitis after transurethral resection

目的：探讨腺性膀胱炎电切治疗后使用吡柔比星联合西施泰进行膀胱灌注治疗的有效性和安全性。方法：回顾性分析我院2009年1月~2013年8月因腺性膀胱炎行经尿道腺性膀胱炎电切术患者158例，按术后膀胱灌注方案不同，分为膀胱灌注无菌透明质酸钠溶液组（A组）、灌注吡柔比星组（B组）、灌注吡柔比星联合无菌透明质酸钠溶液组（C组），术后随访6个月，比较各组的临床疗效差异。结果：A组48例，治愈39例（81．3％），缓解6例（15．4％），无效3例（6．3％）；B组50例，治愈40例（80％），缓解8例（16．0％），无效2例（4．0％）；C组60例，治愈55例（91．7％），缓解5例（8．3％），无无效病例。结论：西施泰联合吡柔比星联合膀胱灌注治疗较单一用药方案更能提高腺性膀胱炎电切术后治愈率，缓解临床症状迅速、持久，耐受性良好。

Objective： To investigate the probability and safety of combined medication of Pirarubicin and Haluronicacid （HA） in bladder irrigation on patients with glandular cystitis after transurethral resection. Methods： Clinical data of 158 cases with glandular cysti- tis （treated with transurethral resection） from January 2009 to August 2013 in our hospital were retrospectively analyzed. All the cases were divided into 3 groups according to the differences among programs that Group A for HA only, Group B for Pirarubicin while Group C with combined medication. The 6 - month - postoperative follow - up will be effective in analyzing the diversity of each group. Results ： 39 of 48 cases in Group A were cured （81.3%）, 6 cases got anesis （ 15.4% ） while 3 ineffectiveness （6.3%）. Group B has 40 cured （ 80% ） , 8 remission （ 16.0% ） and 2 ineffectiveness （4.0%） in all 50 cases. Group C has 55 cured （91.7%） , 5 remission （ 8.3% ） and no ineffectiveness in 60 cases. Conclusion： The combined medication of Pirarubicin and HA in bladder irrigation had a higher cure rate in the treatment of glandular cystitis after transurethral resection than a single medicine. It also should be a rapid and lasting analgesic effect in relieving clinical symptoms, and it should be also well tolerated by patients.